The study evaluates how omega-3 delivery architecture influences triglyceride outcomes and omega-3 incorporation in ...

XI'AN, SHAANXI PROVINCE, CHINA, January 20, 2026 /EINPresswire.com/ -- As global demand for clean-label, functional, ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the Institutional Review Board (“IRB”) at ...

CRANBURY, N.J., March 2, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies ...

Notes: Safety population, includes all randomized subjects who received at least one dose of study drug or placebo. Based on the encouraging weight loss, as well as the safety and tolerability results ...

LYON, France--(BUSINESS WIRE)-- Regulatory News: Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC, the “Company”), the biopharmaceutical company focused on the treatment of diabetes and other ...

- Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly ...

HONG KONG, HONG KONG , HONG KONG, January 21, 2026 /EINPresswire.com/ -- As skincare science rapidly evolves toward ...

The rollout of different vaccines to reduce the risk of transmission and disease severity among patients with the coronavirus disease 2019 (COVID-19) has been historic. However, with every passing day ...

Algernon Pharmaceuticals Inc. AGNPF has set up a clinical research program for the treatment of strokes, focused on its proprietary DMT analogue, AP-188. The company is also planning to begin a Phase ...